Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases To the Editor: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia affecting the frontal and temporal hairlines. 1 The incidence of this condition is increasing, and currently, little is known about the likelihood of stabilization, factors affecting prognosis, and the preferred treatment approach. [2] [3] [4] With institutional review board approval, we reviewed the records of FFA patients with at least 3 months of follow-up and tracked patient progress at each visit by assessing hairline measurements ( from the outer canthi or glabella to frontal hairline) and using trichoscopy (1003 magnification). Disease stabilization was defined as no further hairline recession, eyebrow loss, or evidence of active inflammation (eg, perifollicular erythema, follicular hyperkeratosis). Statistical analyses were conducted using the t test, chi-square test, or Fisher's exact test and log-rank tests.
Our study identified 92 patients (98% of which were women) with FFA; notably, 94.6% of these patients displayed eyebrow involvement (Table I) . Average age of onset for FFA was 55 years, and patients had an average of 21.4 months of follow-up at our clinic (range 3-106 months). Although patients with classic lichen planopilaris typically experience symptoms (including pruritus and pain), 5 only 14.1% of the patients in this study reported symptoms at the initial visit. Approximately 11% of patients had a concomitant autoimmune disease; most commonly hypothyroidism (7.6% of patients). Regarding prognosis, 70.7% (65/92) of patients stabilized with treatment (Table II) after an average of 10.4 (range 1-72) months. Although 27 patients did not stabilize, 10 of them had not yet reached 10 months of follow-up by the time of chart review. We found that a younger age of onset was significantly associated with a less severe disease course ( fewer total centimeters of hairline lost, P ¼ .0012). Family history of hair disorders seemingly did not affect prognosis (P ¼ .4217).
In terms of treatment, 71.7% of patients were treated with intralesional corticosteroids in combination with topical and systemic agents. Because of patient preference, 1 individual was treated using topicals only (tacrolimus and hydrocortisone) and stabilized in 18 months. Nine patients were transitioned to topicals only, either because of disease stabilization or patient preference. Comparisons were made for systemic and topical treatments to determine differences with time to stabilization, likelihood of stabilization, and total centimeters of hairline lost. Our study demonstrated that patients treated with 0.3% tacrolimus were significantly more likely to stabilize in 3 months compared with patients treated with clobetasol/betamethasone (P ¼ .0297). Overall, median times to stabilization were 11.9 months for tacrolimus and 13.2 months for clobetasol/betamethasone. Patients receiving both treatments were removed from the analysis. All patients with severe FFA were offered clobetasol and tacrolimus; however, some patients declined tacrolimus because of cost. We also compared outcomes from patients treated with hydroxychloroquine with those treated with antiinflammatory antibiotics and found no significant differences.
Limitations of this study included retrospective design and small sample size. Currently, there are no validated methods for categorizing disease severity in FFA, which is a limitation to our assessment of treatment responses. Finally, we found that patients treated with doxycycline, tetracycline, or minocycline were significantly more likely to experience adverse medication effects compared with other treatments (P ¼ .0189). Efficacy of topical diphenylcyclopropenone maintenance treatment for patients with alopecia areata: A retrospective study
To the Editor: Diphenylcyclopropenone (DPCP) immunotherapy is widely used in the treatment of alopecia areata (AA). 1 Few studies have described the efficacy of DPCP maintenance treatment (DPCP-MT), and the relapse rate (RR) varies.
2-4 Therefore, we sought to clarify whether DPCP-MT prevents recurrence and to identify associated variables.
Among 230 AA patients treated with DPCP, 63 patients who achieved and maintained a complete response (defined as [90% regrowth) for at least 6 weeks were included (Fig 1) . Forty-one patients who received continuous regular treatments afterwards were classified as the maintenance-treated group. DPCP was applied to the entire scalp, including nonlesional skin and previous AA lesions that had already improved. Twenty-two patients who did not receive further DPCP treatment, including subjects lost to follow-up, were classified as the maintenanceuntreated group. A telephone questionnaire was conducted with 8 patients for whom relapse information was not available because they were lost to follow-up. Relapse was defined as recurrence of $25% hair loss. Interval initial was defined as the number of weeks from the start of treatment with DPCP to the transition to DPCP-MT, and Interval mnt was defined as the number of weeks on DPCP-MT. 
